Despite major interest in this pathway for cancer drug discovery, no drugs have yet been approved that act specifically against PI3K or its downstream regulator, AKT. However, several drugs that ...
Hosted on MSN12mon
Japan approves AstraZeneca’s Truqap with Faslodex for breast cancerProgression-free survival in the overall trial population and subjects with PI3K/AKT pathway alterations were the trial's dual primary endpoints. Results from the trial showed that Truqap plus ...
MedPage Today on MSN8d
Mixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian CancerPromising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback